Clinical Trials

Pancreatic Neoplasms

NCT07097142 2026-04-08

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07276360 2026-03-27

HypoRTCx-UG

278 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02701153 2026-03-10

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

51 enrolled

NCT07447570 2026-03-03

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

27 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04278118 2026-02-17

HiPPI

70 enrolled

CNSEndocrine

Brain Neoplasms, Meningioma, Neurilemmoma, Pituitary Neoplasms, Nerve Sheath Neoplasms

NCT05109494 2026-01-28

Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas

30 enrolled

NCT07188532 2026-01-23

BEAR

141 enrolled

Sarcoma, Ewing

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

118 enrolled

Genitourinary

Prostatic Neoplasms

NCT06559540 2026-01-09

SWIFT RT

220 enrolled

Breast Neoplasms

NCT04683653 2025-12-29

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Phase 1/2 Recruiting

100 enrolled

Gynecologic

Endometrial Neoplasms

NCT06635980 2025-12-12

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

120 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04430452 2025-12-08

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

21 enrolled

Carcinoma, Hepatocellular

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06435260 2025-06-26

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT05136846 2025-06-04

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

Phase 1 Recruiting

28 enrolled

Thoracic

Lung Neoplasms

NCT05439278 2025-05-21

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

178 enrolled

CNS

Glioblastoma

NCT06928584 2025-04-15

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

221 enrolled

Locally Recurrent Rectal Cancer

NCT06796270 2025-01-28

Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma

24 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06160206 2024-11-19

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

134 enrolled

CNS

Glioblastoma

NCT05370144 2024-11-18

A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma

42 enrolled

Esophageal Neoplasms

NCT06593899 2024-09-19

The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities

51 enrolled

NCT04636008 2024-08-06

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Phase 1/2 Recruiting

20 enrolled

Turcot syndrome, Rectal Neoplasms

NCT05443646 2024-05-07

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

55 enrolled

Thoracic

Limited Stage Small Cell Lung Cancer

NCT05491395 2022-08-08

PROMART

120 enrolled

Breast Neoplasms

NCT03829553 2022-06-02

HARVEST

801 enrolled

Breast Neoplasms

NCT04025164 2019-07-18

Hypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery

4,052 enrolled

Breast Neoplasms

NCT03856372 2019-02-27

Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast Cancer

1,494 enrolled